deltatrials
Completed PHASE3 INTERVENTIONAL 4-arm NCT02543268

A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Immunogenicity, Safety and Tolerability of a Heterologous Prime-Boost Regimen Using Three Different Batches of Ad26.ZEBOV and a Single Batch of MVA-BN®-Filo in Healthy Adult Subjects

Sponsor: Crucell Holland BV

Conditions Healthy
Interventions Ad26.ZEBOV-Batch #1 Ad26.ZEBOV-Batch #2 Ad26.ZEBOV-Batch #3 MVA-BN-Filo Placebo
Updated 12 times since 2017 Last updated: Jun 19, 2025 Started: Sep 21, 2015 Primary completion: Jan 22, 2016 Completion: Jul 20, 2016
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Healthy and is currently completed. Crucell Holland BV leads this study, which shows 12 recorded versions since 2015 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotCompleted~Jun 2018 – ~Sep 2020 · 27 months · monthly snapshotCompleted~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshotCompleted~Jan 2021 – ~Apr 2022 · 15 months · monthly snapshotCompleted~Apr 2022 – ~Nov 2023 · 19 months · monthly snapshotCompleted~Nov 2023 – ~Jul 2024 · 8 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – ~Apr 2025 · 7 months · monthly snapshotCompleted~Apr 2025 – ~May 2025 · 30 days · monthly snapshotCompleted~May 2025 – ~Jul 2025 · 2 months · monthly snapshotCompleted~Jul 2025 – present · 12 months · monthly snapshotCompleted

Change History

12 versions recorded

  1. Jul 2025 — Present [monthly]

    Completed PHASE3

  2. May 2025 — Jul 2025 [monthly]

    Completed PHASE3

  3. Apr 2025 — May 2025 [monthly]

    Completed PHASE3

  4. Sep 2024 — Apr 2025 [monthly]

    Completed PHASE3

  5. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

▶ Show 7 earlier versions

  1. Nov 2023 — Jul 2024 [monthly]

    Completed PHASE3

  2. Apr 2022 — Nov 2023 [monthly]

    Completed PHASE3

  3. Jan 2021 — Apr 2022 [monthly]

    Completed PHASE3

  4. Sep 2020 — Jan 2021 [monthly]

    Completed PHASE3

  5. Jun 2018 — Sep 2020 [monthly]

    Completed PHASE3

  6. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

  7. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Sep 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Crucell Holland BV
Data source: Crucell Holland BV

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations